Vital Farms Reaffirms $775M-$800M 2026 Revenue-But That 6.6% Gross Margin Is the Real Test

Vital Farms held 2026 guidance, but Q2 gross margin is the real pressure point

Vital Farms reaffirmed fiscal 2026 net revenue of $775 million to $800 million and adjusted EBITDA of $0 million to $10 million. But the quarter that brought investors to that conclusion was weak: the company reported only 6.6% gross margin in Q2, down from 38.9% a year earlier. For investors, the question is no longer whether Vital Farms still exists as a business. It is whether that guidance can hold while profitability falls apart.

Why investors are focused on the quality of the numbers

Q2 was bad across the income statement. Revenue fell to $166.0 million, down 10.1%, and diluted EPS dropped to a $0.72 loss. The brand is still selling, but each dollar of sales is now producing far less profit than it did a year ago.

The stock reaction showed how uneasy investors are. Shares fell 6.21% to $11.48, still far below the $53.13 52-week high. That leaves the debate simple: is this quarter the trough, or is it another sign that full-year guidance needs to move lower?

The sales story is holding, but the margin story is breaking

The issue is straightforward. Investors are not debating whether Vital Farms still has a real business. They are debating whether guidance remains credible when the economics behind each sale have weakened so sharply. In Q2, the main revenue problem was a $19.8 million volume-driven decrease excluding excess breaker and wholesale sales. The $1.1 million price-and-mix benefit was not enough to offset that decline. At the same time, gross margin fell to 6.6% from 38.9%, a 32.3-point contraction.

Category oversupply is squeezing both price and mix

Q2 guidance did not fail in a vacuum. Egg oversupply drove lower-priced channel sales and input and production costs increased, which helps explain why revenue and margin both weakened. When category pricing softens that hard, holding top-line guidance is much harder even if the brand is still competitive.

Q1 already showed the same problem taking shape

This was not only a Q2 issue. In Q1, revenue still rose 15.4% to $187.2 million, but gross margin had already fallen to 28.3% from 38.5%. That earlier split suggests demand was not fully broken; profitability was the first thing to crack.

Why bulls and bears are reading the same quarter differently

Bulls can point to the fact that Vital grew retail dollar share by more than 200 basis points even as category pricing fell. That suggests the brand is still holding up better than the market environment.

Bears focus on the wider profit swing. A business can gain share and still post a quarter that makes full-year guidance look fragile. For now, the market is waiting for proof that share gains are turning back into healthier gross margin, not just a more defensive narrative.

The real investor test is whether the second half can repair margins

This is no longer just a question of whether Vital Farms can sell enough. It is whether the second half can repair margins before another weak print forces management to cut guidance again.

Fiscal 2025 shows what the business is trying to get back to

Last year matters because it shows this is not a broken brand. Vital still finished 2025 with fiscal 2025 net revenue of $759.4 million, up 25.3% versus fiscal 2024. That gives investors a baseline for what a healthier version of the business looks like.

Liquidity improved, but buybacks stopped

The financing news matters too. Vital announced new aggregate $185 million credit facilities and also terminated its stock repurchase program. That points to a company prioritizing liquidity while the operating environment improves. It reduces near-term financial pressure, but it also removes one more source of demand for the stock.

What the next quarter needs to show

The next report matters less as a validation of the long-term vision and more as a test of repair:

• Positive read: mix improves, volumes stabilize, and gross margin moves meaningfully higher.
• Negative read: margin stays compressed and revenue guidance slips again.

If that happens, the recovery case becomes much easier to believe. If not, investors will keep treating 2026 guidance as a target under pressure rather than a firm commitment.